INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 283 filers reported holding INTELLIA THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,115 | -10.8% | 256,626 | +15.0% | 0.01% | -16.7% |
| Q2 2023 | $9,097 | +8.2% | 223,068 | -1.1% | 0.01% | +50.0% |
| Q1 2023 | $8,408 | -7.3% | 225,653 | -13.2% | 0.00% | 0.0% |
| Q4 2022 | $9,067 | -99.9% | 259,867 | +40.8% | 0.00% | -63.6% |
| Q3 2022 | $10,330,000 | +86.7% | 184,571 | +72.7% | 0.01% | +266.7% |
| Q2 2022 | $5,532,000 | -24.5% | 106,898 | +6.0% | 0.00% | -50.0% |
| Q1 2022 | $7,327,000 | -78.7% | 100,837 | -65.3% | 0.01% | 0.0% |
| Q4 2021 | $34,400,000 | +98.9% | 290,918 | +125.7% | 0.01% | -25.0% |
| Q3 2021 | $17,292,000 | -29.9% | 128,885 | -15.5% | 0.01% | -33.3% |
| Q2 2021 | $24,684,000 | +52.3% | 152,462 | -24.5% | 0.01% | +33.3% |
| Q1 2021 | $16,208,000 | +1646.6% | 201,967 | +1083.4% | 0.01% | – |
| Q4 2020 | $928,000 | +55.4% | 17,066 | -43.2% | 0.00% | – |
| Q3 2020 | $597,000 | -5.5% | 30,059 | +0.1% | 0.00% | – |
| Q2 2020 | $632,000 | +97.5% | 30,037 | +14.8% | 0.00% | – |
| Q1 2020 | $320,000 | -52.1% | 26,163 | -42.5% | 0.00% | – |
| Q4 2019 | $668,000 | +156.9% | 45,527 | +133.0% | 0.00% | – |
| Q3 2019 | $260,000 | -37.0% | 19,538 | -22.6% | 0.00% | – |
| Q2 2019 | $413,000 | +154.9% | 25,244 | +165.2% | 0.00% | – |
| Q1 2019 | $162,000 | -22.5% | 9,519 | -37.7% | 0.00% | – |
| Q4 2018 | $209,000 | -55.2% | 15,287 | -6.2% | 0.00% | – |
| Q3 2018 | $466,000 | +127.3% | 16,305 | +118.4% | 0.00% | – |
| Q2 2018 | $205,000 | -50.7% | 7,466 | -62.3% | 0.00% | – |
| Q1 2018 | $416,000 | +132.4% | 19,778 | +112.8% | 0.00% | – |
| Q4 2017 | $179,000 | +4.1% | 9,295 | +34.2% | 0.00% | – |
| Q3 2017 | $172,000 | +421.2% | 6,928 | +233.2% | 0.00% | – |
| Q2 2017 | $33,000 | -87.6% | 2,079 | -89.0% | 0.00% | – |
| Q1 2017 | $267,000 | +80.4% | 18,872 | +68.3% | 0.00% | – |
| Q4 2016 | $148,000 | +14700.0% | 11,213 | +16389.7% | 0.00% | – |
| Q3 2016 | $1,000 | -90.0% | 68 | -86.1% | 0.00% | – |
| Q2 2016 | $10,000 | – | 490 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Discovery Value Fund | 561,561 | $17,756,559 | 9.73% |
| MPM BioImpact LLC | 544,639 | $17,221,485 | 4.60% |
| Casdin Capital, LLC | 1,178,075 | $37,250,732 | 4.12% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,145,091 | $36,207,777 | 3.72% |
| Atlas Venture Associates IX, LLC | 10,000 | $316,200 | 2.69% |
| Deep Track Capital, LP | 2,000,000 | $63,240,000 | 2.44% |
| ARK Investment Management | 9,948,629 | $314,575,638 | 2.41% |
| Merlin Capital, Inc | 18,526 | $585,792 | 2.19% |
| Orchard Capital Management, LLC | 159,155 | $5,032,481 | 1.86% |
| TANG CAPITAL MANAGEMENT LLC | 397,600 | $12,572,112 | 1.77% |